Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.040
+0.010 (0.97%)
At close: Aug 13, 2025, 4:00 PM
1.060
+0.020 (1.92%)
After-hours: Aug 13, 2025, 7:00 PM EDT
Allogene Therapeutics Employees
As of December 31, 2024, Allogene Therapeutics had 229 total employees, including 226 full-time and 3 part-time employees. The number of employees decreased by 4 or -1.72% compared to the previous year.
Employees
229
Change (1Y)
-4
Growth (1Y)
-1.72%
Revenue / Employee
n/a
Profits / Employee
-$1,034,533
Market Cap
227.48M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALLO News
- 3 hours ago - Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 7 days ago - Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 12 days ago - Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - GlobeNewsWire
- 2 months ago - Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha
- 2 months ago - Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
- 2 months ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - GlobeNewsWire